Abstract: A sterile pharmaceutical composition having as its active principles piperacillin sodium and tazobactam sodium of substantially the same density, mixed with sodium bicarbonate. The mixture is soluble in water to give injectable reconstituted solutions having high stability with time.

Abstract: Mixtures of at least two active principles, of which at least one is the sodium salt, are precipitated from an organic solution containing the same active principles in salified or non-salified acid form.

Abstract: Cefalotin is methoxylated in position 7?, desacetylated and then carbamoylated in position 3, to provide acid cefoxitin without any isolation of intermediate products. The acid cefoxitin is then transformed into the sodium salt by means of ion exchange resin.

Abstract: Process for producing Cefepime, Cefpirome and Cefquinome, whereby a cephalosporin containing a quaternary ammonium group is reacted with thiourea to provide the aforesaid cephalosporins.

Abstract: A sterile pharmaceutical composition having as its active principles piperacillin sodium and tazobactam sodium of substantially the same density, mixed with sodium bicarbonate. The mixture is soluble in water to give injectable reconstituted solutions having high stability with time.

Abstract: Mixtures of at least two active principles, of which at least one is the sodium salt, are precipitated from an organic solution containing the same active principles in salified or non-salified acid form.

Abstract: Cefalotin is methoxylated in position 7?, desacetylated and then carbamoylated in position 3, to provide acid cefoxitin without any isolation of intermediate products. The acid cefoxitin is then transformed into the sodium salt by means of ion exchange resin.

Abstract: Cephalosporins may be conveniently prepared by a process in which a benzathinium salt of formula (V) wherein: Z is benzathine; and X and R2 are as defined in the specification, is reacted with thiourea. The resulting product may be crystallized as a sodium salt, as an internal salt, or as a pharmaceutically acceptable salt.

Abstract: Process for producing Cefepime, Cefpirome and Cefquinome, whereby a cephalosporin containing a quaternary ammonium group is reacted with thiourea to provide the aforesaid cephalosporins.

Abstract: Cephalosporins may be conveniently prepared by a process in which a benzathinium salt of formula (V) wherein: Z is benzathine; and X and R2 are as defined in the specification, is reacted with thiourea. The resulting product may be crystallized as a sodium salt, as an internal salt, or as a pharmaceutically acceptable salt.

Abstract: Cephalosporins may be conveniently prepared by a process in which 7-ACA is silylated, acylated, desilylated and then salified to give an intermediate which is eventually cyclized with thiourea.

Abstract: A bioavailable crystalline form of cefuroxime axetil, obtained by treating known crystalline or amorphous cefuroxime axetil with water or with a water-miscible organic solvent or with a mixture thereof at a temperature of between +20.degree. C. and +100.degree. C., followed by cooling and separating the crystalline product by known methods.

Abstract: The invention relates to a substantially anhydrous crystalline cefadroxil having a water content between about 0.8% and 3.9%.Such cefadroxil is obtained slurrying a cefadroxil solvate of dimethylacetamide, or of N-methyl-2-pyrrolidone or of monomethylformamide, with isopropyl alcohol with up to 4% of water and preferably in the presence of methanol in an amount lower than 60%, at a temperature of about +45.degree. C. to +55.degree. C. and then filtering the so obtained compound.

Abstract: The invention relates to a novel crystalline cefadroxyl hemihydrate having a K.F. between about 3.5 and 2.0%: such compound is more stable than other cefadroxyl molecules.The novel cefadroxyl is obtained preparing and isolating a novel cefadroxil solvate of dimethylacetamide, or of N-methyl-2-pyrrolidone or of monomethylformamide, slurrying and solvate with a mixture methanol/isporpyl alcohol 30:70 to 50:50 by volume at a temperature of about +45.degree. C. to +55.degree. C. and then filtering the so obtained compound.

Abstract: The invention relates to a novel crystalline cefadroxyl hemihydrate having a K.F. between about 3.5 and 2.0%: such compound is more stable than other cefadroxyl molecules.The novel cefadroxyl is obtained preparing and isolating a novel cefadroxil solvate of dimethylacetamide, or of N-methyl-2-pyrrolidone or of monomethylformamide, slurrying said solvate with a mixture methanol/isopropyl alcohol 30:70 to 50:50 by volume at a temperature of about +45.degree. C. to +55.degree. C. and then filtering the so obtained compound.

Abstract: The invention relates to a method for producing crystalline cefadroxil hemihydrate. According to the method a cefadroxil solvate is slurried with a mixture methanol:isopropyl alcohol 30:70 to 70:30 by volume containing from 5% to 12% of water, a temperature from +45.degree. C. to +55.degree. C. and then isolating the so obtained crystalline compound.

Abstract: The invention relates to a method for preparing crystalline cefadroxil monohydrate.According to such a method a cefadroxil solvate is slurried with isopropyl alcohol containing less 6% to 18% of water at a temperature between +45.degree. to +55.degree. C.: the crystalline cefadroxil monohydrate is isolated by filtration.Some of the cefadroxil solvates which can be used are novel: they are prepared by adding dimethylacetamide, N-methyl-2-pyrrolidone or monomethylformamide to an aqueous solution of cefadroxil at a pH between 5.5 and 6.

Abstract: There are provided 3-azinomethyl rifamycins of the formula I: ##STR1## wherein R represents hydrogen or acetyl;R.sub.1 represents hydrogen or lower alkyl;R.sub.2 represents an alkyl group having from 2 to 4 carbon atoms substituted by a dialkoxy group each having from 1 to 3 carbon atoms;R.sub.3 represents an alkyl group having from 1 to 4 carbon atoms;R.sub.2 and R.sub.3 may form with the amino nitrogen atom a 4- to 8-membered heterocyclic ring, having a maximum of two hetero atoms, substituted by hydroxy-, alkoxy-, dialkoxy- or alkylenedioxy groups each having from 1 to 4 carbon atoms, arylalkoxyimino groups having from 7 to 9 carbon atoms, acyloxy groups having from 1 to 4 carbon atoms;R.sub.1 and R.sub.2 may form with the amino nitrogen atom and the carbon atom a 5 to 7-membered heterocyclic ring optionally substituted by alkyl or alkoxy group having from 1 to 4 carbon atoms.The compounds display antibacteria activity against Gram-positive and Gram-negative bacteria and Mycobacteria.

Abstract: There are provided azino rifamycin compounds of the formula (I): ##STR1## Y.dbd.H or CH.sub.3 CO; R.sub.1 linear or branched C.sub.1 -C.sub.7 alkyl or C.sub.3 -C.sub.4 alkenyl- R.sub.2 =linear or branched C.sub.1 -C.sub.7 alkyl, C.sub.2 -C.sub.4 chloroalkyl, C.sub.3 -C.sub.4 alkenyl, Cycloalkyl having 3 to 7 C atoms in the ring, cycloalkyl alkyl having 3 to 6 C atoms in the ring, phenyl, or C.sub.7 -C.sub.8 aralkyl, unsubstituted or mono-substituted by a halogen atom in the aryl group; or NR.sub.1 R.sub.2 =a cyclic moiety having 5 to 8 C atoms, unsubstituted or substituted by 1 or 2 CH.sub.3 groups, morpholino.The compounds inhibit the growth of gram positive bacteria and Mycobacterium tuberculosis.Oxidized compounds, preparative methods and pharmaceutical compositions are also described and claimed.

Abstract: A process for the preparation in homogeneous phase and in quantitative yield of 3-iminomethyl derivatives of rifamycin SV useful as antibiotic agents. Rifamycin S is reacted in an organic solvent .Iadd.with a compound .Iaddend. ##STR1## to give a solution of .[.1,3-oxazino-(5,6-c) rifamycins.]. .Iadd.an intermediate compound .Iaddend.which is treated with an organic solvent at a pH from 4 to 6. The aqueous phase is discharged and the organic phase is treated with an amine .Iadd.or hydrazine .Iaddend.under basic conditions, the desired derivatives being finally isolated from this organic phase according to usual techniques.